NASDAQ: DNLI

Denali Therapeutics (NASDAQ: DNLI) has announced disappointing results from a Phase II trial of its RIPK1-targeted small-molecule drug for amyotrophic lateral sclerosis (ALS). The drug, developed in partnership with France-based Sanofi Inc. (NASDAQ: SNY), failed to meet the primary endpoint in the Phase II HIMALAYA study, which assessed the change…